In the natural history of a disease define: total preclinical phase, detectable pre-clinical phase and clinical phase. Suppose on 10 am on 25.01.2010 a disease A onset you biologically. Suppose test of the disease A can detect it exactly after completion of 1000 days of biologically onset. Suppose signs and symptoms develop exactly after completion of 1010 days of biologically onset. Suppose you consult doctor exactly after 1015 days of biologically onset of the disease. Suppose outcome the treatment is cure. What is duration of (i) total preclinical phase (ii) detectable pre-clinical phase (iii) clinical phase.
In the natural history of a disease, the following terms are defined:
1. Total preclinical phase: This is the period from the biological onset of the disease until the appearance of the first clinical symptoms or signs.
2. Detectable preclinical phase: This is the portion of the total preclinical phase during which the disease can be detected by specific tests or investigations, even though no clinical symptoms or signs ___ _____ ___ ______ _____ __________.
____ _______ ___ ____ ____.
_______ ________ __________ _________ _______ _______ _____ __________ _______ ______ _____ _______.
_________ ____ _____ ___ _______ ____.
_______ ________ _____ ____ _______ ______ ________ ____.
___ _______ _______ _____ _______ ______ ____ ___ ___ _________.
____ ________ __________ __________ __________ __________ _____ __________ ______ _______ ____ ____.
__________ ___ ______ _______ _________ _______ _____.
______ _____ ___ _______ ________ __________ _____ _________ __________ ________.
________ ________ _______ __________ _____ _________ ____ __________.
___ ________ _____ __________ __________ _______ ___ _______ ________ ____ _________.
_______ __________ ________ _______ _____ __________ ____ ___.
_____ __________ _______ ______ _____ _______ __________ ___ ______ ___ ___ __________.
______ __________ __________ __________ _________ _________ ____ _________ _______ _______.
_______ ________ _______ ___ __________ _________ __________.
_________ __________ _____ ____ _______ _____ __________ ______ _______ ___.
__________ _________ ______ __________ ____ _____ _______ _____ _______ _________.
_________ _______ _____ _______ _________ _____ ___ ___.
______ ___ ____ _______ _______ __________ ________ ____.
__________ ___ _______ ____ ________ _______ ____ ______ __________ ____ _____ ___.
________ _________ __________ ____ __________ ____.
_______ ___ __________ __________ ____.
_______ ____ ______ _________ ______ ________.
__________ ________ __________ ______ ______ _____ ___ _____ _____ ____.
Get Full Answer on WhatsApp
In usual notations you are given the following information Find the sample size. If power of the test is 95% instead of 80%, then find new sample size.
If p denotes proportion and q denotes odds then prove that Find the range of q. If the odds of smokers in a study are 0.25 then find the proportion of smokers in the study. Assume that each subject of the study is either a smoker or non-smoker.
In the natural history of a disease define: total preclinical phase, detectable pre-clinical phase and clinical phase. Suppose on 10 am on 25.01.2010 a disease A onset you biologically. Suppose test of the disease A can detect it exactly after completion of 1000 days of biologically onset. Suppose signs and symptoms develop exactly after completion of 1010 days of biologically onset. Suppose you consult doctor exactly after 1015 days of biologically onset of the disease. Suppose outcome the treatment is cure. What is duration of (i) total preclinical phase (ii) detectable pre-clinical phase (iii) clinical phase.
If you are told that haemoglobin (Hb) level in blood measures the iron content. The normal level in healthy people is around 15 g/dL. Most Indian women have less and some have even less than 8 g/dL. They are called anemic. Iron supplementation is given to increase this level. Suppose one supplementation increase the mean Hb level in anemics by 3.2 g/dL, after one month of use and the other by 3.6 g/dL, in an equivalence trial on 500 women each. The respective SD’s of the of the increases are 0.52 and 0.72 g/dL. The doctors determine that the supplementations can be clinically equivalent if the difference between the increases by two supplementations does not exceed 0.52 g/dL. Can these two supplementations be considered clinically equivalent at 5% level of significance?
A trial is conducted in which some people with disease X were randomly allocated into twogroups. First group was advised to do some morning walk for 30 minutes and take light foodeach day and second group was given one injection and one 100 mg tablet once a day tocontrol disease X. The injection can cause loose motion in some cases and 100 mg tablethas no side effect. At the end of two months, 90% of group I and 80% of group II had
recovered from disease X.
i) What are the regimens for group I and group II in this trial?
ii) What are the efficacies in group I and group II?
iii) What are the safety issues in group I and group II in this trial?
RTPCR test is applied on 300 covid patients and 200 non-covid patients. The results of the test are shown as follows.
| Disease status | ||||||
| Yes (D + ) | No (D - ) | Total | ||||
| Result of RTPCR test | T+ | 480 | 40 | 520 | ||
| T - | 120 | 360 | 480 | |||
| Total | 600 | 400 | 1000 | |||
What is the basic difference between (a) cross-sectional (b) cohort and (c) case control study designs. Explain with suitable examples of each design.